Veracyte, Inc.
General ticker "VCYT" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $2.6B (TTM average)
Veracyte, Inc. follows the US Stock Market performance with the rate: 42.6%.
Estimated limits based on current volatility of 2.4%: low 40.79$, high 42.82$
Factors to consider:
- Total employees count: 824 (+1.1%) as of 2024
- US accounted for 95.0% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Operational and conduct risks, Regulatory and compliance, Market competition, Cybersecurity threats, Geopolitical risks
- Price in estimated range
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [32.44$, 57.37$]
- 2025-12-31 to 2026-12-31 estimated range: [29.56$, 53.10$]
Financial Metrics affecting the VCYT estimates:
- Negative: with PPE of 48.5 at the end of fiscal year the price was high
- Positive: -5.02 < Operating profit margin, % of 3.62
- Positive: 1.77 < Return on assets ratio (scaled to [-100,100]) of 1.82
- Positive: Inventory ratio change, % of 0.55 <= 0.82
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: -4.41 < Investing cash flow per share per price, % of -1.83
- Positive: Shareholder equity ratio, % of 90.46 > 64.17
- Negative: negative Industry operating cash flow (median)
Short-term VCYT quotes
Long-term VCYT plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $296.54MM | $361.05MM | $445.76MM |
| Operating Expenses | $337.62MM | $446.85MM | $429.62MM |
| Operating Income | $-41.08MM | $-85.80MM | $16.14MM |
| Non-Operating Income | $4.65MM | $9.18MM | $9.60MM |
| Interest Expense | $0.00MM | $0.00MM | $0.00MM |
| R&D Expense | $40.60MM | $57.30MM | $69.29MM |
| Income(Loss) | $-36.43MM | $-76.61MM | $25.74MM |
| Taxes | $0.13MM | $-2.21MM | $1.61MM |
| Profit(Loss)* | $-36.56MM | $-74.40MM | $24.14MM |
| Stockholders Equity | $1,075.20MM | $1,044.10MM | $1,175.97MM |
| Inventory | $14.29MM | $16.13MM | $21.75MM |
| Assets | $1,156.42MM | $1,114.91MM | $1,300.04MM |
| Operating Cash Flow | $7.54MM | $44.22MM | $75.10MM |
| Capital expenditure | $8.55MM | $9.96MM | $11.29MM |
| Investing Cash Flow | $-29.39MM | $15.11MM | $-56.27MM |
| Financing Cash Flow | $3.49MM | $2.84MM | $4.90MM |
| Earnings Per Share** | $-0.51 | $-1.02 | $0.32 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.